Journals / Turkish Journal of Hematology / 2011 / Cilt: 28 - Sayı: 2

Multipl miyelomda T düzenleyici hücreleri ile otolog çevre kanı kök hücre nakli arasındaki korelasyonun araştırılması

The correlation between T regulatory cells and autologous peripheral blood stem cell transplantation in multiple myeloma

Pages
107–114
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Relationship of Tregs with prognosis needs to be determined by studies that include larger cohorts.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Multiple myeloma (MM) is characterized by malignant proliferation of plasmocytes and their precursors.
📊
Key Findings & Data:The aim of this study was to compare CD4+CD25+FOXP3+ Treg, CD200, and PD-1 levels in MM patients that did and did not undergo APBSCT.
💡
Conclusion & Impact:Relationship of Tregs with prognosis needs to be determined by studies that include larger cohorts.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Multiple myeloma (MM) is characterized by malignant proliferation of plasmocytes and their precursors. T regulatory cells (Tregs) have a role in immunosuppression and control of autoim- munity, and are currently an important topic in the study of immune response to tumor cells. The correlation between Tregs and autologous peripheral blood stem cell transplantation (APBSCT) in MM has not been studied. The aim of this study was to compare CD4+CD25+FOXP3+ Treg, CD200, and PD-1 levels in MM patients that did and did not undergo APBSCT. Materials and Methods: Peripheral blood samples were collected from 28 MM patients ranging in age from 41 to 78 years for analysis of CD4CD25+ FOXP3+ Tregs, PD-1 (CD279), and CD200. Peripheral blood mononuclear cells were isolated via density gradient centrifugation. Four-color flow cytometry was performed. Using a sequential gating strategy, Tregs were identified as CD4+CD25+FOXP3+ T-cells. Results were analyzed using the Mann Whitney U non-parametric test and a compare means test. p values <0.05 were considered statistically significant. Results: The study included 28 MM patients (10 female and 18 male). In all, 11 of the patients under- went APBSCT. The level of Tregs identified as CD4+CD25+FOXP3+ T-cells was higher in the patients that underwent APBSCT (p=0.042). CD200 and PD-1 levels did not significantly differ between the 2 groups (p=0.711 and p=0.404, respectively). There weren&#8217;t any statistically significant differences in CD200, PD-1, or CD4+CD25+FOXP3+ T-cell levels between the patients that did and did not undergo APBSCT (p>0.05). Conclusion: Treg levels were higher in the patients that underwent APBSCT. Tregs are crucial for the induction and maintenance of peripheral tolerance to self-antigens. In addition, Tregs can suppress immune responses to tumor antigens; however, APBSCT and Treg levels were not correlated with CD200 or PD-1 expression. Relationship of Tregs with prognosis needs to be determined by studies that include larger cohorts.

Özet

Amaç: Multipl miyelom (MM) plazmositlerin ve bunların öncü hücrelerinin habis proliferasyonu ile kendini gösteren bir hastalıktır. T düzenleyici (regülatör) hücreler (Treg) immünsüpresyonda ve oto- immün sistemin denetiminde rol oynarlar. Ayrıca tümör hücrelerine karşı oluşan immün yanıttaki rolleri de güncel bir araştırma konusudur. Treg hücreleri MM’da otolog çevre kanı kök hücre nakli (APBSCT) ile ilişkili olarak daha önce araştırılmamıştır. Bu çalışmanın amacı, CD4+ CD25+ FoxP3+ Treg hücreleri ile, CD200 ve PD–1 ‘in APBSCT yapılmış ve yapılmamış MM hastalarındaki düzeylerini karşılaştırmaktır. Yöntem: Yaşları 41 ile 78 arasında 28 MM hastasından CD4+ CD25+ FoxP3+ Treg hücreleri ile, CD200 ve PD–1 (CD279) analizi için çevre kanı örnekleri alındı. Mononükleer hücreler dansite gradient santrifüj yöntemi ile ayrıldı. Dört renkli akış sitometri ile uygulandı. Ardışık kapılamalar (gating) ile Treg hücreleri CD4+ CD25+ FoxP3+ T hücreleri olarak tanımlandı. Sonuçlar Mann Whitney U nonparametrik testi ve Compare Means testleri ile analiz edildi. P değerleri 0.05). Sonuç: Bu çalışmada Treg hücreleri APBSCT yapılmış hastalarda daha yüksek düzeyde bulunmuştur. Treg hücrelerinin bireyin kendi hücrelerine karşı periferik toleransın indüklenmesinde ve korunmasında çok önemli rolü olduğu bilinmektedir. Buna ek olarak, Treg hücreleri tümör antijenlerine karşı oluşturulacak immün yanıtı baskılayabilmektedir. Ne var ki, çalışmamızda APBSCT veya Treg hücre düzeyleri CD200 ve PD-1 ekspresyonları ile korelasyon göstermemiştir. Prognoz ile ilişkileri daha fazla sayıda olgu grupları içeren çalışmalarla aydınlatılabilir.

🔖

Cite This Article

ERÇETİN, A. P., AKTAŞ, S., PİŞKİN, Ö., ATEŞ, H., ZADEOĞLULARI, Z. F., TURGUT, N. H., ÖZCAN, M. A. (2011). Multipl miyelomda T düzenleyici hücreleri ile otolog çevre kanı kök hücre nakli arasındaki korelasyonun araştırılması. Turkish Journal of Hematology, Cilt: 28 - Sayı: 2, 107–114. https://ajindex.com/articles/413340

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G. Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program 2003;248-78.
  2. Schwartz RN, Vozniak M. Current and emerging treat- ments for multiple myeloma. J Manag Care Pharm 2008;14:12-9.
  3. Durie BG, Salmon SE. A clinical staging system for mul- tiple myeloma. Cancer 1975;36:842-54. [CrossRef] Greipp PR, San Miguel JF, Durie BG. International Staging System for multiple myeloma. J Clin Oncol 2005;23:3412-20. [CrossRef] Mollee P Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev 2009;30:93-103.
  4. Bommert K, Bargou RC, Stuhmer T. Signalling and sur- vival pathways in multiple myeloma. Eur J Cancer 2006;42:1574-80. [CrossRef] Ander KC. Targeted therapy of multiple myeloma based upon tumor microenvironmental interactions. Exp Hematol 2007;35:155-62.
  5. Cools N, Ponsaerts P Van Tendeloo VF, Berneman ZN. Regulatory T cells and human disease. Clin Dev Immunol 2007;2007:89195. [CrossRef] Mottet C, Golshayan D. CD4+CD25+FOXP3+ Regulatory T cells: from basic research to potential therapeutic use. Swiss Med Wkly 2007;137:625-34.
  6. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61. [CrossRef] Prabhala RH, Neri P Bae JE, Tassone P Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC. Dysfunctional T regula- tory cells in multiple myeloma. Blood 2006;107:301-4.
  7. Minas K, Liversidge J. Is the CD200/ CD200 receptor interaction more than just a myeloid cell inhibitory signal. Crit Rev Immunol 2006; 26:213-30.
  8. Moreaux J, Veyrune JL, Reme T, De Vos J Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 2008;366:117-22. [CrossRef] Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P Bourin P Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194-7. [CrossRef] Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T cell immunity. Immunology 2007;19:309-14. [CrossRef] Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293-7. [CrossRef] 17. Franceschini D, Paroli M, Francavil